Study on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung Cancer

Exclusion Criteria

• •Patients with large cell neuroendocrine tumors and mixed small cell carcinoma;
• •Patients with active brain metastasis or central nervous system invasion confirmed by imaging evaluation and/or biopsy (prednisone equivalent dose ≥ 10mg);
• •There is an hypersensitivity reaction to any investigational drug or its components;
• •Severe uncontrolled concurrent infections or other serious uncontrolled concomitant diseases, moderate or severe kidney injury; (such as progressive infection, uncontrollable hypertension, diabetes, etc.);
• •Heart function and disease meet one of the following conditions:
• •1. Long QTc syndrome or QTc interval\>480 ms;
• •2. Complete left bundle branch block, II or III degree atrioventricular block;
• •3. Severe and uncontrolled arrhythmias that require medication treatment;
• •4. The New York College of Cardiology has a classification of ≥ III;
• •5. Cardiac ejection fraction (LVEF) below 50%;
• •6. A history of myocardial infarction, unstable angina, severe unstable ventricular arrhythmias, or any other arrhythmias requiring treatment, a history of clinically severe pericardial disease, or evidence of acute ischemic or active conduction system abnormalities on electrocardiogram within the 6 months prior to recruitment.
• •Active infection of hepatitis B and hepatitis C (hepatitis B B virus surface antigen is positive and hepatitis B B virus DNA exceeds 1x103 copies/mL; hepatitis C virus RNA exceeds 1x103 copies/mL);
• •Human Immunodeficiency Virus (HIV) infection (HIV antibody positive);
• •Has previously or currently suffered from other malignant tumors (except for effectively controlled non melanoma skin basal cell carcinoma, breast/cervical carcinoma in situ, and other malignant tumors that have not been treated and have been effectively controlled within the past five years);
• •Pregnant and lactating women, as well as patients of childbearing age who are unwilling to take contraceptive measures;
• •Patients with other malignant tumors that require treatment; The researchers determined that patients who are not suitable to participate in this study.